Loading
Every dated change on the records linked to Osteosarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.
A milestone in how this cancer is treated.
15-year all-cause mortality among five-year survivors fell from 12.
Poor responders: EFS HR 0.
A milestone in how this cancer is treated.